Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 643, Nantes, France.
PLoS One. 2011;6(5):e19321. doi: 10.1371/journal.pone.0019321. Epub 2011 May 16.
The state of operational tolerance has been detected sporadically in some renal transplanted patients that stopped immunosuppressive drugs, demonstrating that allograft tolerance might exist in humans. Several years ago, a study by Brouard et al. identified a molecular signature of several genes that were significantly differentially expressed in the blood of such patients compared with patients with other clinical situations. The aim of the present study is to analyze the role of one of these molecules over-expressed in the blood of operationally tolerant patients, SMILE or TMTC3, a protein whose function is still unknown.
METHODOLOGY/PRINCIPAL FINDINGS: We first confirmed that SMILE mRNA is differentially expressed in the blood of operationally tolerant patients with drug-free long term graft function compared to stable and rejecting patients. Using a yeast two-hybrid approach and a colocalization study by confocal microscopy we furthermore report an interaction of SMILE with PDIA3, a molecule resident in the endoplasmic reticulum (ER). In accordance with this observation, SMILE silencing in HeLa cells correlated with the modulation of several transcripts involved in proteolysis and a decrease in proteasome activity. Finally, SMILE silencing increased HeLa cell sensitivity to the proteasome inhibitor Bortezomib, a drug that induces ER stress via protein overload, and increased transcript expression of a stress response protein, XBP-1, in HeLa cells and keratinocytes.
CONCLUSION/SIGNIFICANCE: In this study we showed that SMILE is involved in the endoplasmic reticulum stress response, by modulating proteasome activity and XBP-1 transcript expression. This function of SMILE may influence immune cell behavior in the context of transplantation, and the analysis of endoplasmic reticulum stress in transplantation may reveal new pathways of regulation in long-term graft acceptance thereby increasing our understanding of tolerance.
在一些停止使用免疫抑制剂的肾移植患者中,偶尔会检测到免疫耐受状态,这表明人类可能存在同种异体移植耐受。几年前,Brouard 等人的一项研究确定了一组分子的特征,这些分子在这些患者的血液中与其他临床情况的患者相比存在显著差异表达。本研究的目的是分析在免疫耐受患者血液中过度表达的一种分子,SMILE 或 TMTC3 的作用,这是一种功能尚不清楚的蛋白质。
方法/主要发现:我们首先证实,与稳定和排斥患者相比,无药物长期移植物功能的免疫耐受患者血液中的 SMILEmRNA 存在差异表达。我们使用酵母双杂交方法和共聚焦显微镜的共定位研究进一步报告了 SMILE 与 PDIA3 的相互作用,PDIA3 是一种驻留在内质网(ER)中的分子。与这一观察结果一致,SMILE 在 HeLa 细胞中的沉默与涉及蛋白酶解的几种转录物的调节以及蛋白酶体活性的降低相关。最后,SMILE 沉默增加了 HeLa 细胞对蛋白酶体抑制剂硼替佐米的敏感性,硼替佐米通过蛋白过载诱导内质网应激,并增加 HeLa 细胞和角质形成细胞中应激反应蛋白 XBP-1 的转录表达。
结论/意义:在这项研究中,我们表明 SMILE 通过调节蛋白酶体活性和 XBP-1 转录物表达参与内质网应激反应。SMILE 的这种功能可能会影响移植背景下免疫细胞的行为,而移植中内质网应激的分析可能会揭示长期移植物接受的新调节途径,从而增加我们对耐受的理解。